# Use of Eylea for the Treatment of an Optic Nerve Hemangioma

> **NCT01714115** · — · NO_LONGER_AVAILABLE · sponsor: **Vitreous -Retina- Macula Consultants of New York**

## Conditions studied

- Retinal Hemangioma

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT01714115
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714115, "Use of Eylea for the Treatment of an Optic Nerve Hemangioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01714115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*